Close Menu

Fluidigm

Fluidigm's mass cytometry and microfluidics research product sales were negatively impacted by the COVID-19 pandemic.

In a marked contrast to its negative performance in February and March, the GenomeWeb Index rose more than 18 percent in April.

Fluidigm's Biomark HD microfluidic platform will enable more than 180,000 real-time PCR tests to be run over the next 90 days to potentially support COVID-19 screening.

Single-cell and single-molecule proteomics tools developed for the immuno-oncology market are proving useful for studying the immune response in COVID-19.

The company expects Q1 revenues of $27.6 million compared to $30.1 million in the year-ago period due to a "significant slowdown" in customer activity.

Both studies emerged from the ongoing Human Cell Atlas project and could help scientists decide on the best approaches to use in various contexts.

The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.

Bioinformatics firm Next Gen Diagnostics will integrate Fluidigm's Juno microfluidic sample prep system into its workflow for pathogen whole-genome sequencing.

Oslo-based InstruNor's systems will enable Fluidigm to offer fully automated, walkaway sample preparation for flow and mass cytometry.

Fourth quarter revenues of $32.4 million were in line with previously reported preliminary revenues and ahead of the Wall Street estimate of $30.8 million.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.